Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus TRICHLORMAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus TRICHLORMAS.
BENICAR HCT vs TRICHLORMAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
TRICHLORMAS is a sedative-hypnotic agent. Its mechanism of action is not fully understood but is believed to involve potentiation of GABAergic inhibition in the central nervous system, similar to other chloral derivatives. It is metabolized to trichloroethanol, which is the active hypnotic compound.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
500 mg orally once daily at bedtime, increased as needed to a maximum of 1 g per day in divided doses; for insomnia, 1-2 g orally at bedtime.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal elimination half-life is approximately 8-11 hours for the parent drug in adults with normal renal function. In patients with hepatic impairment, half-life may be prolonged up to 30 hours; in severe renal impairment, half-life of metabolites may increase significantly.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Primarily renal via glomerular filtration and tubular secretion; about 70-80% of the dose excreted unchanged in urine within 24 hours. The remainder is metabolized to trichloroethanol (active) and trichloroacetic acid; these metabolites are also eliminated renally.
Category C
Category C
ARB + Thiazide Diuretic
Thiazide Diuretic